Home / 2020 / May / 19

Daily Archives: May 19, 2020

Meltwater Announces New Product Updates and a New Corporate Website

SAN FRANCISCO, May 19, 2020 (GLOBE NEWSWIRE) — Meltwater, a global leader in media intelligence, today announces its Aurora Product Release, detailing a range of solutions, workflows and new functionality in its flagship product. The release follows the success of the Fjord Product Release last October, and the release name is another nod to Meltwater’s Norwegian heritage. Meltwater has also launched a brand new website, which articulates everything that the company now offers, and how they help to bring Marketing, PR and Communications teams closer together, with an intuitive, all-in-one solution.

The Aurora release focuses on three main themes: capturing more content and conversations than anyone else, advancing analytics into insights, and prioritizing simplicity for users.

Meltwater believes that content is king, and prides itself on capturing more content and conversations than anyone else, across the most media types. Recent updates include:

  • The addition of podcast monitoring, giving customers the ability to monitor more than 25,000 podcasts globally in real-time
  • Double the amount of content from Reddit, one of the world’s fastest-growing social networks
  • An improved network of print and broadcast monitoring partners around the world

The second theme is around advancing analytics to insights, to help our customers stay on top of market-moving announcements in real-time, and with workflows that support ad-hoc searching, automated reporting, and comprehensive event analysis. In this release, this is highlighted by:

  • The launch of Signals, which provides real-time notifications on significant news items on the companies you care about, powered by Artificial Intelligence
  • Recent advancements in Explore, such as the ability to filter by author lists, compare searches to one another, and an integration into our Audience Insights module for in-depth audience segmentation and analysis
  • New workflows around dashboard curation and interactive event analysis, to help customers go from information to insights as quickly as possible

By prioritizing simplicity and efficiency, Meltwater continues to focus on user experience for all customers. A new design and navigation were announced in the Fjord release, and we are now bringing to market:

  • ‘Quick find’ capability, so that customers can go immediately to any other asset from any page they are on throughout the application.
  • ‘Labels,’ allowing users to more effectively categorize their saved searches to help them stay organized and collaborate across teams.
  • ‘Combined searches,’ which allow for aggregate analysis across searches and filter sets, to ensure consistency of reporting across business units and global teams.

“As we strive to help bridge the gap between Marketing, PR and Communications teams on a global scale, we are excited to deliver on the types of solutions that can help these teams work more collaboratively together. Through investments in new content types, better insights, and a more elegant user experience, we are excited to deliver more value to our customers and to package that up in our Aurora release,” said Tim Santos, VP of Product Management at Meltwater.

Coinciding with the Aurora release, Meltwater is also launching a new corporate website. “Our new website reflects the products and solutions that we make available to modern marketing and PR professionals today. We have developed solutions at an impressive rate over the past few years, and the new website showcases a lot of those updates, while also providing a wealth of resources to help our customers and visitors better plan and execute on their strategy in an ever-changing landscape”, said Angela Wiesenmueller, Director of Marketing, EMEA.

Meltwater’s new website can be found at http://www.meltwater.com, and more information around the Aurora release can be found here.

About Meltwater
Meltwater was founded in 2001 as the world’s first online media monitoring company. Today, we are a global leader in media intelligence and social analytics, helping to bridge the gap between Public Relations, Communications and Marketing departments with an intuitive, all-in-one solution powered by AI-driven insights. Over 30,000 of the world’s most respected brands rely on Meltwater to help inform their strategic decision-making, and with over 55 offices across six continents, Meltwater is a truly global partner. We are also proud to own and operate the Meltwater Entrepreneurial School of Technology (MEST), a pan-African entrepreneurial program & incubator, fostering the next generation of African tech talent. Learn more at meltwater.com.

Contact:
Johnny Vance
Global Head of Product Marketing and Partnerships
johnny.vance@meltwater.com

Teledyne’s new SWIR line scan camera enables defect detection beyond the visible

The first SWIR line scan camera from Teledyne DALSA offers up to 74 dB dynamic range and spectral response from 950 to 1700 nm

Teledyne DALSA’s first Linea SWIR line scan camera

The Linea SWIR camera features a cutting-edge InGaAs sensor

WATERLOO, Canada, May 19, 2020 (GLOBE NEWSWIRE) — Teledyne DALSA, a Teledyne Technologies [NYSE:TDY] company and global leader in machine vision technology, is pleased to announce its first short-wave infrared (SWIR) line scan camera for machine vision. The new Linea SWIR features a cutting-edge InGaAs sensor in a compact package suitable for a variety of applications including food and packaged good inspection, recycling, mineral sorting and solar and silicon wafer inspection.

With exceptional responsivity and low noise, this newest Linea SWIR line scan camera allows customers to see their products in a new light. Linea SWIR is a 1k resolution camera with highly responsive 12.5 µm pixels, 40 kHz line rate, cycling mode, programmable I/Os, power over Ethernet (PoE), precision time protocol (PTP), and more.

“The new Linea SWIR will help customers greatly improve the quality of their output,” said Mike Grodzki, Product Manager for the new Linea SWIR. “With the ability to differentiate materials and detect moisture, Linea SWIR will allow customers to more easily identify foreign contaminants in their product stream. And its capacity to image beyond the visible spectrum makes the camera ideal for applications such as food sorting, solar wafer inspection, and consumer packaged goods inspection.”

Key Features:

  • High responsivity low noise 1k sensor
  • GigE interface
  • HDR and Cycling modes
  • High dynamic range
  • Programmable I/Os
  • Selectable 8 or 12 bit output
  • Flat field correction
  • ROI support

For more information about the Linea SWIR visit the website. For high quality images, please visit our online media kit.

Teledyne DALSA is part of the Teledyne Imaging group and a world leader in the design, manufacture and deployment of digital imaging components for the machine vision market. Teledyne DALSA image sensors, cameras, smart cameras, frame grabbers, software, and vision solutions are used in thousands of automated inspection systems around the world and across multiple industries including semiconductor, solar cell, flat panel display, electronics, automotive, medical, packaging and general manufacturing. For more information, visit www.teledynedalsa.com/mv.

Teledyne Imaging is a group of leading-edge companies aligned under the Teledyne umbrella. Teledyne Imaging forms an unrivalled collective of expertise across the spectrum with decades of experience. Individually, each company offers best-in-class solutions. Together, they combine and leverage each other’s strengths to provide the deepest, widest imaging and related technology portfolio in the world. From aerospace through industrial inspection, scientific research, spectroscopy, radiography and radiotherapy, geospatial surveying, and advanced MEMS and semiconductor solutions, Teledyne Imaging offers world-wide customer support and the technical expertise to handle the toughest tasks. Their tools, technologies, and vision solutions are built to deliver to their customers a unique and competitive advantage.

All trademarks are registered by their respective companies.
Teledyne DALSA reserves the right to make changes at any time without notice.

Media Contact:
Geralyn Miller
Global Media Relations                     
519-886-6000 ext. 2187                                                                                              
geralyn.miller@teledyne.com

Sales Contacts:
Sales.americas@teledyne.com
Sales.europe@teledyne.com
Sales.asia@teledyne.com

Radient Technologies Inc. Announces Collaboration on the Development of Anti-Viral Products and Files Patent Application Covering Cannabinoid Based Compositions for the Mitigation and Protection from Viruses

EDMONTON, Alberta, May 19, 2020 (GLOBE NEWSWIRE) — Radient Technologies Inc. (“Radient” or the “Company”) (TSX Venture: RTI; OTCQX: RDDTF), a commercial manufacturer of high quality cannabinoid-based ingredients, formulations and products, announces that it has filed a provisional patent application covering the use of a combination of cannabinoids, terpenes and zinc (the “Formulations”) as a means of preventing infection of coronavirus, mitigating the symptoms of coronavirus, and lowering infectiousness of Covid-19 patients, with the goal of reducing hospitalizations and intensive care unit requirements. Additionally, the Company announces that it will lead a collaboration with two US based groups, IntuitiveX (“IntuitiveX”) and ipCapital Group (“ipCapital”), to explore the development of new anti-viral products using the Formulations.

The Company is not making any express or implied claims as to the effectiveness of the Formulations or its ability to mitigate the symptoms of, eliminate, cure or contain Covid-19 (or SARS-2 Coronavirus), and there can be no assurance that the Formulations will be effective or reach commercial production. The Company plans to collaborate with IntuitiveX and ipCapital to develop a process and timeline for the development of the Formulations.

Patent Application

The Company has filed a provisional patent application with the US Patent and Trademark Office (“USPTO”) that covers the Formulations as a means of preventing infection of, mitigating the symptoms of, and lowering infectiousness of viral respiratory infections, including Covid-19, in patients.

“Filing this patent application with the USPTO gives us an international priority date that will allow us to nationalize in other selected jurisdictions in the future, including, for example, Canada, Europe and Asia,” said Dr. Steven Splinter, Chief Technology Officer of Radient.

Collaboration

The Company announced that it will be collaborating with ipCapital, IntuitiveX and a third party contract research organization to be determined with a goal of developing, clinically testing and marketing cannabinoid based products that are targeted at lessening and/or eliminating the effects of Covid-19 in patients.

“We are excited to announce this important initiative, which brings together our team of experienced research scientists along with scientific, regulatory and technology expertise that each of these groups possess. We believe this collaboration will greatly assist with the development pathway for the Formulations,” said Denis Taschuk, Chief Executive Officer of Radient.

The Company, ipCapital and their advisors have done a review of existing scientific literature that has focused on the use of cannabinoids and/or zinc compounds for anti-inflammatory and anti-viral indications.  The Company believes there is sufficient scientific evidence from its review to support exploring the efficacy of the Formulations. As previous research work has been done by other groups on the use of cannabinoids or zinc for anti-viral purposes, the Company will be looking to validate that work through its own efforts with the specific viral target for this project. It is expected that Radient’s dedicated innovation laboratory will lead the product development and the Company’s proprietary processing technology will be used to produce the high-purity cannabinoids required for this product.

Dr. Anna Bakowska-Barczak, Director of Formulations and Product Development at Radient will oversee the formulation development for patient studies.  She has over 15 years of process/product development, formulation, and regulatory experience. She currently leads Radient’s formulation and product development team and has developed and continues to develop a broad range of proprietary cannabinoid-based product formulations for both medical and consumer markets.  Dr. Bakowska-Barczak is a recognized expert in formulation and product development for food and nutraceutical markets, including cannabis. She holds Engineering and Master Degrees in Food Science and received her Ph.D. in Food Science in 2005. She has authored or co-authored over 30 peer-reviewed scientific publications and is the inventor of 13 patent applications.

The Company has developed significant cannabinoid expertise as a result of its research efforts of the last three years.  During this time the Company built up its scientific team to include over 25 in house scientists and engineers and has invested over $5 million on its research, process development and intellectual property portfolio.  The Company has developed, during this time, a number of proprietary formulations that it hopes will form the base of the development of a final formulation(s) for this Covid-19 program. As well, the Company believes that it has the necessary equipment to develop and manufacture the necessary product formulations for patient studies including analytical testing of the composition of the formulations.

IntuitiveX, a Seattle, Washington based life sciences advisory firm that has a long work-ing history with ipCapital, and is closely associated with one of Seattle’s leading hospitals, will act as a service provider. It will lead the efforts associated with testing, regulatory approvals and additionally, incorporate their advanced monitoring capabilities allowing for rapid collection and evaluation of data.

ipCapital Group, a leading Intellectual Property(“IP”) consulting firm, based in Williston, Vermont, has been assisting the Company with its IP strategy for two years and will lead the IP and innovation strategy for the project.

“We are happy to be part of this collaboration to advise on the IP strategy and the IP development,” says John Cronin, Managing Director of ipCapital. Together, the three companies, and through their networks, have strong product development, clinical and regulatory expertise.  Additionally, the Company expects to support its patient study activities by adding a third party contract research organization to assist in the design, execution and evaluation of results of patient studies required.

The group will be working to develop new anti-viral products, initially targeted at Covid-19, that the group hopes will provide mitigation in the form of reduction of symptoms leading to fewer hospitalizations and reduced ICU requirements. “Our goal is to combine two over-the-counter anti-inflammatory/anti-viral mitigators that are already well appreciated in research: cannabinoids and zinc,” said Dr. Splinter. “There is a body of evidence that cannabinoids and their receptors influence viral pathogenesis, viral replication and of course the immune system itself.  Further, other research has shown the inhibitory effect of zinc on viruses that attack the respiratory tract, including for example rhinovirus.  We believe that the combination could potentially be an effective anti-viral treatment.”

The Company envisions starting patient studies with residents of long term care facilities, currently expected to be in the Seattle, Washington area, in order to test the efficacy of the Formulations both on high risk staff as well as nursing home patients. Radient is also considering exploring the use of the Formulations to mitigate ongoing symptoms of certain post Covid-19 survivors, notably those with continued pulmonary fibrotic disease. No such patient studies have been scheduled as of yet, and there is no certainty that any such patient studies will be scheduled.

Key milestones for the project would include 1) completion of final formulations including dosing determination, 2) patient study design including identification of test sites and study leaders, 3) regulatory approval of study and 4) execution of study with evaluation of results.

About Radient

Radient Technologies is a commercial manufacturer of high quality cannabinoid based formulations, ingredients and products. Utilizing a proprietary extraction and downstream processing platform that recovers up to 99% of cannabinoids from the cannabis plant, Radient develops specialty products and ingredients that contain a broad range of cannabinoid and terpene profiles while meeting the highest standards of quality and safety. Please visit www.radientinc.com for more information.

About IntuitiveX

IntuitiveX is a life science consultancy and incubator created to help entrepreneurs and startups transform their ideas from concept to commercialization. IntuitiveX has a team of business, legal, clinical, scientific and intellectual property domain experts with over 50+ years of combined experience who provide a full spectrum of services to entrepreneurs and startups.

About ipCapital

ipCapital, celebrating 22 years in business, with over 1000 clients, serving >15% of the F500 and hundreds of medium and small businesses using its interdisciplinary team of consultants and advisors and programmers who are all focused on maximizing clients’ financial results. ipCapital combines its world-class human capital with its proprietary AI based tools and methodologies around innovation, invention, and Intellectual Property.

SOURCE: Radient Technologies Inc.

Contact for Radient: Investor Relations: ir@radientinc.com

Contact for Intuitive-X: Simon Robinson: srobinson@intuitive-x.com

Contact for ipCapital: Seth Cronin: scronin@ipcg.com

Forward Looking Information:
This press release contains “forward-looking information” within the meaning of applicable Canadian securities legislation. Forward-looking information includes, without limitation, statements regarding the Company’s ability to obtain approvals for its patents, the Company’s expectations with respect to the efficacy of the Formulations, the Company’s ability to develop and commercialize anti-viral products, the Company’s ability to effectively study the use of the Formulations, including through patient studies, the Company’s collaboration with ipCapital and IntuitiveX and the Company’s future plans. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects” or “does not expect”, “is expected”, “budget”, “scheduled”, “estimates”, “goal”, “forecasts”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved”. Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Radient, as the case may be, to be materially different from those expressed or implied by such forward-looking information. Although Radient has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking information. Radient does not undertake to update any forward-looking information, except in accordance with applicable securities laws.

NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Toka Selected by Chile and Inter-American Development Bank to Assess and Support Chile’s National Cybersecurity Readiness

The IDB-funded project will help Chile respond to emerging cybersecurity threats

TEL AVIV, Israel, May 19, 2020 (GLOBE NEWSWIRE) — Toka, the cyber capacity-building company for government agencies, has been selected by the Government of Chile and the Inter-American Development Bank (IDB) to advise Chile on next steps for the country’s national cybersecurity readiness and operational capacity building. Toka will assess current cybersecurity gaps and challenges in Chile and support the IDB project implementation by recommending specific cybersecurity readiness improvements.

The capacity building project, funded by the IDB, will strengthen Chile’s cybersecurity, build the country’s long-term resilience to digital threats, and establish Chile as a cybersecurity leader in South America. Following the May 2018 cyberattack on Banco de Chile, Chilean leaders accelerated the implementation of the national cybersecurity strategy approved in 2017 in order to address these emerging challenges. Toka supports the ongoing implementation of Chile’s national strategy and will suggest improvements to Chile’s technological tools, infrastructure, training programs, and cybersecurity policies.

“In today’s ever-changing landscape of cyber threats, the Inter-American Development Bank understands that countries of all sizes all over the world must be proactive and regularly look for new ways to protect their vital infrastructure and their people,” said Yaron Rosen, CEO and co-founder of Toka. “We’re thankful our trusted partnerships with established organizations like the IDB provided us with this opportunity to work with the Government of Chile on the country’s cybersecurity resilience.”

Toka is the first company to tackle these emerging threats by merging cutting-edge innovation with bold, strategic thinking about national cybersecurity matters. Toka develops high-end intelligence gathering capabilities to strengthen homeland security and can address the full breadth of defensive cybersecurity needs, including developing new technologies when required. Toka also works with other international organizations to offer unique “Cyber Designer Services” to government agencies, advising them on the strategies, processes, technologies, and personnel development needed to keep their critical infrastructure, digital landscape, and government institutions secure.

Headquartered in Tel Aviv, Israel, Toka was founded by leaders with unparalleled experience in the political, military, and corporate worlds. The Toka team includes members who have worked at the highest levels of Israel’s national cybersecurity ecosystem, spearheading the development of Israel’s National Cyber Agency, the first of its kind in the world. Its founding team includes: retired Brig. Gen. Yaron Rosen, former Chief of Israel Defense Forces Cyber Staff; Alon Kantor, former Vice President of Business Development for CheckPoint; Kfir Waldman, former CEO of cyber and mobile companies Kayhut and Go Arc; and Ehud Barak, former Israeli Prime Minister and Minister of Defense.

About Toka
A strong national cyber defense and resilience are the keys to protecting any country’s systems, people, and digital economy from dynamic threats. Toka builds targeted and lawful intelligence gathering platforms to effectively gather intelligence from various sensors. These first-of-their-kind software platforms are simple to use, scale quickly, and offer complete operational control to enable smarter, faster, and easier investigations and operations.

Toka’s unique Cyber Designer Services provide agencies with the full-spectrum strategies, customized projects, and technologies needed to keep critical infrastructure, the digital landscape, and government institutions secure and durable, while adhering to leading industry-recognized security standards. Toka helps design, build, and manage a tailored ecosystem of cyber capabilities and software products for governmental, law enforcement, and security agencies.

Founded by leaders with unparalleled experience in the strategic, defense, and corporate worlds, Toka works across the strategic, operational, and tactical levels, and has deep, hands-on technical experience, to address the full breadth of its clients’ cybersecurity needs, including developing new technologies when required. Toka is headquartered in Tel Aviv, Israel, and backed by investors such as: Andreessen Horowitz, Eclipse Ventures, Dell Technologies Capital, Entrée Capital, and Launch Capital. For more information, go to: tokagroup.com.

Contact:
Kenneth Baer, press@tokagroup.com
(202) 792-7200

CCD Image Sensor Technology Plays Key Role in COVID-19 Diagnostics

Image sensor technology from Teledyne e2v drives microscopy research and diagnosis of novel coronavirus and other diseases

Teledyne e2v CCD77-358 image sensor

Teledyne e2v CCD77-358 in production

CHELMSFORD, United Kingdom, May 19, 2020 (GLOBE NEWSWIRE) — Teledyne is supplying high performance charged coupled devices (CCDs) for COVID-19 diagnostic scientific instruments. These highly sensitive image sensors are used for low-light imaging applications such as microscopy and other scientific imaging techniques deployed for research and diagnostic testing of COVID-19.

In the past few weeks, the UK CCD Fabrication team have been producing hundreds of CCD77-358 devices that will be designed into camera systems to support COVID-19 diagnostics.

Miles Adcock – President – Teledyne e2v Space & Quantum said: “The Coronavirus outbreak has triggered increased demand and interest for CCD and CMOS sensors. We expect to have manufactured several times the forecasted annual demand for the CCD77-358 devices by the end of this quarter alone. Our ability to expedite and meet urgent requirements is testament to the drive and commitment of the Chelmsford CCD Fabrication Operations team.”

The CCD77-358 sensor is back-illuminated and has an image resolution of 512 x 512 pixels, a large pixel size of 24µm in size and a high dynamic range.

Teledyne has advanced wafer-processing facilities in the UK and Canada. Testament to the resilience of CCD technology in the most demanding applications, Teledyne is committed to the provision of a long-term vertically integrated, dedicated CCD fab and continues to make technology developments to the design and production of CCDs.

Further images available from the Teledyne Imaging News here.

Notes to editors:

About Teledyne e2v

Teledyne e2v is a part of the Teledyne Imaging group. Their innovations lead developments in healthcare, life sciences, space, transportation, defense and security, and industrial markets. Teledyne e2v’s unique approach involves listening to the market and application challenges of customers and collaborating with them to provide innovative standard, semi-custom or fully-custom imaging solutions, bringing increased value to their systems.

In combination with its sister companies, Teledyne DALSA and Teledyne Imaging Sensors, three imaging powerhouses, together represent a new paradigm in the delivery of innovative imaging solutions built on unrivalled expertise and a deep technological heritage that includes capabilities across the spectrum, from infrared to x-ray imaging.

Teledyne Imaging is a group of leading-edge companies aligned under the Teledyne umbrella. Teledyne Imaging forms an unrivalled collective of expertise across the spectrum with decades of experience. Individually, each company offers best-in-class solutions. Together, they combine and leverage each other’s strengths to provide the deepest, widest imaging and related technology portfolio in the world. From aerospace through industrial inspection, scientific research, spectroscopy, radiography and radiotherapy, geospatial surveying, and advanced MEMS and semiconductor solutions, Teledyne Imaging offers world-wide customer support and the technical expertise to handle the toughest tasks. Their tools, technologies, and vision solutions are built to deliver to their customers a unique and competitive advantage.

Contact:

Mark Bown, Head of Marketing – Space Imaging
mark.bown@teledyne.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/6b78c748-544e-44da-8faa-a290b379f525

Philips launches HealthSuite Clinical Trial Accelerator to help life science organizations run more flexible, patient-centric clinical trials

May 19, 2020

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced Clinical Trial Accelerator on Philips HealthSuite. This new tailored set of capabilities allows life science organizations to integrate, analyze and store clinical and patient-reported data from multiple sources, providing actionable insights for better, faster decision-making.

Philips HealthSuite is an integrated, modular set of standards-based capabilities that support the development of digital propositions across the health continuum, encompassing HIPAA compliant, secure cloud capabilities. Clinical Trial Accelerator enables patient-centric trials at home, managing the collection of data while providing the security and compliance expected from both patients and life science organizations.

Life science organizations face continued pressure to run more efficient, cost-effective clinical trials. Empowering patients and making it easier for them to stay connected and contribute to a trial can have a significant impact on compliance rates and overall success. At the same time, collecting data and identifying actionable insights while ensuring the security and compliance of patient information is key. Clinical Trial Accelerator is designed to address these challenges, helping life science organizations reach their goals faster and supporting greater flexibility in trial design.

“Philips HealthSuite already provides cloud-based services and tools to a wide array of healthcare organizations, and with Clinical Trial Accelerator we have created a tailored set of capabilities to support life science organizations,” said Dale Wiggins, General Manager for the HealthSuite digital platform at Philips. “Our innovative, flexible cloud platform leverages our global healthcare capabilities and is supported by our compliance, security and interoperability expertise.”

Tailored capabilities to accelerate clinical trials
Other HealthSuite capabilities include an AI Analytics Workbench for enhanced decision making and standards-based interoperability for Digital Imaging and Communication in Medicine (DICOM) data, as well as the HealthSuite Clinical Data Lake, a new scalable micro-service that acts as a centralized big data repository for high-volume clinical data collection studies and includes controls to curate and manage data in a manner that addresses regulatory requirements.

These HealthSuite capabilities offer companies cloud-based services and technical tools that meet privacy, security and regulatory requirements that they can use to develop and run a new generation of connected healthcare applications. Unlike other digital platforms, HealthSuite is purpose-built to solve the complex challenges of healthcare, featuring capabilities to manage device data, collect personal and health data, store and share data securely, analyze data, build and deploy AI models, and create solutions on the cloud.

In addition, these HealthSuite capabilities power a wide range of both Philips and 3rd party connected healthcare applications in areas including image-guided therapy, sleep and respiratory care, ophthalmology, telehealth and self-medication. For 3rd party collaborations, Philips is the provider of the relevant cloud-based healthcare IT infrastructure and is not involved in the commercialization of the products and services of these companies. More information on Philips HealthSuite can be found at www.philips.com/healthsuite.

For further information, please contact:

Mark Groves
Philips Global Press Office
Tel: +31 631 639 916
Email: mark.groves@philips.com
Twitter: mark_groves

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2019 sales of EUR 19.5 billion and employs approximately 81,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachments

SmileDirectClub Files $2.8 Billion Lawsuit Against NBC Over Defamatory And Error-Filled ‘Nightly News’ Story

Story Had 40+ Errors, Ignored Facts Handed to Reporter Prior to Broadcast

NBC News Never Intended to Tell the Truth, Suit Claims

NASHVILLE, Tenn., May 18, 2020 (GLOBE NEWSWIRE) — SmileDirectClub, Inc. (NASDAQ: SDC) the oral care company and first direct-to-consumer medtech platform for teeth straightening, announced today that it has filed a lawsuit seeking approximately $2.8 billion from NBC Universal Media (“NBC”) and reporter Vicky Nguyen for knowingly and intentionally making factually inaccurate, misleading and defamatory claims about the Company and its platform on an NBC Nightly News with Lester Holt report.

NBC’s February 13, 2020 ‘Nightly News’ report contained more than 40 false and misleading statements about SmileDirectClub and the treatment patients receive from the hundreds of board-certified doctors who use the company’s platform to treat patients, the Company said in the lawsuit filed at the state courthouse in Nashville. SmileDirectClub’s reputation was wrongly sullied and its business unjustly harmed as a result of the NBC story according to the suit.

“The breadth of its misconduct is staggering,” the Company said in the 205-page lawsuit. “NBC misled its viewers and readers about the safety of the treatment that patients receive when using SDC’s platform, the involvement of licensed dentists and orthodontists in the treatment of patients when using SDC’s platform, and the benefits that patients receive when they are treated using SDC’s platform. Incredibly, nearly everything that NBC stated and implied about SDC in its broadcast and online report was factually inaccurate.”

The Company added, “Making matters worse, NBC knew it was not telling the truth to its viewers and readers.”

In the wake of NBC’s report, and as a direct result of it, SDC’s market cap plummeted by $950 million. As provided for by law, SmileDirectClub is seeking to recover treble damages pursuant to Tennessee’s Consumer Protection Act.

“SmileDirectClub gave NBC every opportunity to retract this defamatory report and correct the record voluntarily. NBC choose not to so. At that point, the company had no choice but to bring this lawsuit to defend its brand and the reputation of hundreds of doctors who are using SmileDirectClub’s telehealth platform to treat patients every day,” said J. Erik Connolly, Vice Chair of the Litigation Practice Group at Benesch, Friedlander, Coplan & Aronoff, and outside counsel for SmileDirectClub. “With this lawsuit, SmileDirectClub is not just holding NBC accountable for its misconduct, but it is also telling its affiliated doctors and shareholders that SmileDirectClub stands by their side and will fight to protect their interests and reputations.”

According to the lawsuit, prior to NBC publishing its reports, SmileDirectClub made available to NBC hundreds of pages of documents demonstrating the safety and effectiveness, and benefits, of the treatment patients receive using the company’s telehealth platform.

Additionally, SmileDirectClub made senior officers available to NBC to answer questions and arranged interviews with doctors who treat patients using SDC’s platform, as well as with many of the more than 750,000 patients whose lives have been changed for the better as a result of the treatment they received.

NBC chose to ignore this information and these sources because it never intended to publish the truth, according to the lawsuit.

“NBC must be held accountable for its abuse of power and betrayal of trust,” the Company said in the lawsuit. “Viewers and readers across the country turn to the media for the information they need to make decisions about their health and well-being. NBC abused their trust by publishing reports about SDC that were littered with false and misleading statements. NBC’s misconduct not only financially injured SDC, but it also prevented patients from seeking the affordable treatment they need for their orthodontic problems and caused investors to lose millions, if not billions, of dollars.”

About SmileDirectClub
SmileDirectClub, Inc. (Nasdaq: SDC) (“SmileDirectClub”) is an oral care company and creator of the first direct-to-consumer medtech platform for teeth straightening, now also offered directly via dentist and orthodontists’ offices. Through our cutting-edge teledentistry technology and vertically integrated model, we are revolutionizing the oral care industry, from clear aligner therapy to our affordable, premium oral care product line. SmileDirectClub’s mission is to democratize access to affordable and convenient care, unleashing the power of a person’s smile to positively impact their place in the world. SmileDirectClub is headquartered in Nashville, Tennessee and operates in the U.S., Canada, Australia, New Zealand, United Kingdom, Ireland, Germany and Hong Kong. For more information, please visit SmileDirectClub.com.

Contact: SmileDirectClub Media Relations: Press@SmileDirectClub.com